Mayne Pharma Group Limited
MAYNF
$3.29
-$0.23-6.54%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 69.42M | 71.38M | 66.05M | 65.92M | 61.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 69.42M | 71.38M | 66.05M | 65.92M | 61.24M |
| Cost of Revenue | 26.78M | 27.54M | 28.82M | 28.77M | 26.77M |
| Gross Profit | 42.64M | 43.84M | 37.23M | 37.15M | 34.47M |
| SG&A Expenses | 41.16M | 42.33M | 35.82M | 35.74M | 43.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.17M | 73.18M | 67.93M | 67.79M | 73.89M |
| Operating Income | -1.75M | -1.80M | -1.88M | -1.87M | -12.65M |
| Income Before Tax | -4.80M | -4.93M | -37.96M | -37.89M | -24.40M |
| Income Tax Expenses | 1.71M | 1.76M | -5.65M | -5.64M | -1.41M |
| Earnings from Continuing Operations | -6.51M | -6.69M | -32.31M | -32.25M | -22.99M |
| Earnings from Discontinued Operations | -1.82M | -1.87M | -1.85M | -1.85M | -1.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.32M | -8.56M | -34.16M | -34.09M | -22.99M |
| EBIT | -1.75M | -1.80M | -1.88M | -1.87M | -12.65M |
| EBITDA | 7.98M | 8.21M | 8.00M | 7.98M | -1.57M |
| EPS Basic | -0.11 | -0.11 | -0.43 | -0.43 | -0.29 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.14 |
| EPS Diluted | -0.11 | -0.11 | -0.43 | -0.43 | -0.29 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.04 | -0.04 | -0.14 |
| Average Basic Shares Outstanding | 79.09M | 79.09M | 78.88M | 78.88M | 80.36M |
| Average Diluted Shares Outstanding | 79.09M | 79.09M | 78.88M | 78.88M | 80.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |